BIOAB (BIOAB) News
Follow BIOAB (BIOAB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Leqembi Sales Total JPY 32.2 Billion in Q3 2026
BioArctic said partner Eisai published preliminary global Leqembi revenue of JPY 32.2 billion for the third quarter of 2026, alongside Biogen's quarterly report.
EQUITY | Oct 28, 2026, 10:26 AM UTC
L
BioArctic begins first Leqembi treatment at private Sweden clinic
BioArctic says Leqembi is now available at a private clinic in Sweden, with the first early Alzheimer's patient starting treatment.
EQUITY | Sep 22, 2026, 02:43 PM UTC
M
First patient treated with Leqembi in Sweden via private clinic
BioArctic AB said Leqembi (lecanemab) is now available at a private clinic in Sweden, with the first patient starting treatment.
EQUITY | Sep 22, 2026, 02:43 PM UTC
M
Japan approves Leqembi Pen subcutaneous dosing for early Alzheimer’s
BioArctic said partner Eisai gained Japanese approval for Leqembi Pen, a once-weekly 500 mg subcutaneous autoinjector for early Alzheimer’s, complementing the IV form.
REGULATION | Sep 16, 2026, 06:20 AM UTC
M
BioArctic gets approval to initiate Leqembi subcutaneous treatment in China
BioArctic AB says Leqembi’s subcutaneous formulation has been approved for initiation treatment in China.
GEOPOLITICS | Sep 03, 2026, 04:04 AM UTC
M
BioArctic: Canada drug agency issues final positive Leqembi reimbursement recommendation
BioArctic says Canada's drug agency issued a final positive recommendation supporting public reimbursement of Leqembi.
EQUITY | Sep 01, 2026, 05:26 AM UTC
L
BioArctic AB (publ) share and voting rights as of Aug 31, 2026
Number of shares and votes for BioArctic AB (publ) as of August 31, 2026.
EQUITY | Aug 31, 2026, 03:57 PM UTC
L
BIOA_B: Leqembi's subcutaneous launch and new partnerships drive growth, with strong financials supporting R&D
BIOA_B: Leqembi's subcutaneous launch and new partnerships drive growth, with strong financials supporting R&D
EQUITY | Aug 26, 2026, 08:26 AM UTC
L
BioArctic files interim report for April–June 2026
BioArctic said it has published an interim report covering the period April–June 2026.
EQUITY | Aug 26, 2026, 06:44 AM UTC